Pulse Biosciences, Inc. (PLSE) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001625101

Add ratio to table...

About

Pulse Biosciences, Inc. (PLSE) operates in the medical device industry, a highly competitive and regulated field. The company specializes in the development and commercialization of its Nano-pulse Stimulation (NPS) technology, which is utilized to treat various medical conditions, including atrial fibrillation (AF), a prevalent heart arrhythmia. Pulse Biosciences generates revenue through the sale of its products, such as the CellFX System. This is a tunable, software-enabled, console-based platform intended for physicians' clinical workflow. It...

Pulse Biosciences, Inc. (PLSE) operates in the medical device industry, a highly competitive and regulated field. The company specializes in the development and commercialization of its Nano-pulse Stimulation (NPS) technology, which is utilized to treat various medical conditions, including atrial fibrillation (AF), a prevalent heart arrhythmia.

Pulse Biosciences generates revenue through the sale of its products, such as the CellFX System. This is a tunable, software-enabled, console-based platform intended for physicians' clinical workflow. It is used to treat benign skin lesions and other medical conditions. The company's primary products include the CellFX System and the CellFX nsPFA 360° Cardiac Catheter, designed for treating AF.

In the realm of cardiology, Pulse Biosciences' Cardiac Program AF stands out. This program addresses AF, a condition caused by faulty electrical signals in the heart. Given the aging population, the prevalence of AF is increasing significantly. Pulse Biosciences believes its NPS technology is uniquely suited to treat AF and has the potential to offer significant advantages over standard thermal modalities.

To this end, the company has developed a cardiac ablation clamp and a cardiac ablation catheter that use NPS technology for AF treatment. The cardiac ablation clamp is designed for surgical procedures performed by cardiac surgeons, while the cardiac ablation catheter is designed for minimally invasive procedures performed by electrophysiologists. A clinical study in Prague, Czech Republic, has been initiated to test the CellFX nsPFA 360° Cardiac Catheter in patients with AF. Additionally, the company has filed a premarket notification 510(k) with the FDA for clearance to commercialize its cardiac ablation clamp in the United States.

The CellFX System is a versatile platform that can accommodate various clinical workflows preferred by physicians. It treats benign skin lesions and other medical conditions using the company's NPS technology. The CellFX System received 510(k) clearance from the FDA in February 2021 and CE marking approval in January 2021, permitting its marketing in the European Union.

Pulse Biosciences faces competition from established technologies in cardiology, oncology, and dermatology, as well as in minimally invasive procedures. Nevertheless, the company believes its NPS technology is unique and differentiated, offering significant advantages over standard thermal modalities.

The company's workforce is committed to providing a respectful environment and offers a comprehensive benefits package, including medical, dental, vision, life and disability plans, and an employee assistance program. As of December 31, 2023, Pulse Biosciences had 56 employees, primarily located at its headquarters in Hayward, California.

Investment thesis

Bull case

The company’s initial revenue of $86,000 is an almost negligible fraction of the procedural volume, which already exceeds 200 patients in the third quarter. Most of these cases are conducted under pilot programs or ongoing clinical studies, meaning the true commercial potential is substantially hidden. The market may therefore be underestimating the revenue upside once the pipeline shifts from study to fully commercialized procedures. As adoption rates rise, the incremental revenue per procedure could accelerate, creating a compounding effect that is not yet reflected in the current financials.
The early clinical data for the nPulse Cardiac Catheter demonstrate an impressive 100% procedural success at six months and 96% at twelve months with only a 1.3% serious adverse event rate. These figures far exceed the typical 20‑25% recurrence rate observed with radiofrequency and cryoablation, indicating a strong therapeutic advantage. The durability of the lesions, as evidenced by 3‑month mapping data, suggests that long‑term efficacy will be maintained, reducing repeat procedures and enhancing patient satisfaction. Such robust outcomes could unlock preferential reimbursement positioning and accelerate market penetration among electrophysiology practices.
nsPFA’s non‑thermal mechanism translates into fewer collateral injuries, lower risk of phrenic nerve damage, and a reduced likelihood of pulmonary vein stenosis. The clinical implications are twofold: a safer profile that appeals to clinicians and a shorter procedural workflow that lowers operating room time and cost. Payors are increasingly attentive to procedural efficiency and safety metrics when determining coverage levels, so the technology’s intrinsic advantages could drive faster payer adoption. Over time, the economic benefits could reinforce the value proposition and create a self‑reinforcing cycle of utilization.
The company’s multi‑indication strategy—targeting thyroid nodules, atrial fibrillation, and surgical ablation—creates a diversified revenue moat. Success in one domain can provide data and credibility that accelerate acceptance in the others. For example, positive safety outcomes in atrial fibrillation can reassure surgeons contemplating the cardiac clamp for concomitant procedures. This cross‑application synergy reduces overall business risk by spreading it across distinct therapeutic areas.
The appointment of Maria Sainz to the board signals a strategic intent to strengthen commercialization capabilities. Her track record with high‑growth medical device firms suggests she will help refine go‑to‑market strategies and negotiate pivotal partnerships. The board’s enhanced expertise can accelerate the company’s transition from clinical validation to commercial deployment. Market participants may not fully appreciate the immediate impact of this leadership change on future execution.

The company’s initial revenue of $86,000 is an almost negligible fraction of the procedural volume, which already exceeds 200 patients in the third quarter. Most of these cases are conducted under pilot programs or ongoing clinical studies, meaning the true commercial potential is substantially hidden. The market may therefore be underestimating the revenue upside once the pipeline shifts from study to fully commercialized procedures. As adoption rates rise, the incremental revenue per procedure could accelerate, creating a compounding effect that is not yet reflected in the current financials.
The early clinical data for the nPulse Cardiac Catheter demonstrate an impressive 100% procedural success at six months and 96% at twelve months with only a 1.3% serious adverse event rate. These figures far exceed the typical 20‑25% recurrence rate observed with radiofrequency and cryoablation, indicating a strong therapeutic advantage. The durability of the lesions, as evidenced by 3‑month mapping data, suggests that long‑term efficacy will be maintained, reducing repeat procedures and enhancing patient satisfaction. Such robust outcomes could unlock preferential reimbursement positioning and accelerate market penetration among electrophysiology practices.
nsPFA’s non‑thermal mechanism translates into fewer collateral injuries, lower risk of phrenic nerve damage, and a reduced likelihood of pulmonary vein stenosis. The clinical implications are twofold: a safer profile that appeals to clinicians and a shorter procedural workflow that lowers operating room time and cost. Payors are increasingly attentive to procedural efficiency and safety metrics when determining coverage levels, so the technology’s intrinsic advantages could drive faster payer adoption. Over time, the economic benefits could reinforce the value proposition and create a self‑reinforcing cycle of utilization.
The company’s multi‑indication strategy—targeting thyroid nodules, atrial fibrillation, and surgical ablation—creates a diversified revenue moat. Success in one domain can provide data and credibility that accelerate acceptance in the others. For example, positive safety outcomes in atrial fibrillation can reassure surgeons contemplating the cardiac clamp for concomitant procedures. This cross‑application synergy reduces overall business risk by spreading it across distinct therapeutic areas.
The appointment of Maria Sainz to the board signals a strategic intent to strengthen commercialization capabilities. Her track record with high‑growth medical device firms suggests she will help refine go‑to‑market strategies and negotiate pivotal partnerships. The board’s enhanced expertise can accelerate the company’s transition from clinical validation to commercial deployment. Market participants may not fully appreciate the immediate impact of this leadership change on future execution.

Bear case

Net losses of $19.4 million in Q3 reflect a high burn environment that is not yet offset by meaningful revenue. Stock‑based compensation rose to $5.6 million, constituting 38% of the year‑over‑year increase in expenses, signaling potential dilution and shareholder value erosion. The company’s cash runway, while sufficient at present, is being consumed at a rate that may necessitate additional fundraising before commercialization yields revenue. If the company cannot secure strategic financing or equity infusions, it risks running out of capital while still investing heavily in clinical studies.
The bulk of procedural volume is still confined to pilot programs and clinical trials, with only a modest $86,000 in revenue. The conversion of these pilots into fully commercial accounts is uncertain; the company has yet to demonstrate that practitioners will adopt the technology at scale beyond early adopters. If the transition stalls, the revenue pipeline will remain thin, limiting the ability to cover operating costs and invest in growth. This scenario exposes the business to a prolonged period of negative earnings and cash depletion.
Payer coverage remains unestablished for many of the company’s indications. While preliminary claims data are positive, the absence of a clear reimbursement framework could delay or reduce the reimbursement rates for procedures performed under the technology. Payers may demand robust real‑world evidence before granting full coverage, and delays in reimbursement approvals could compress margins for early adopters. The company’s ability to secure favorable payer terms is therefore a critical, but currently uncertain, driver of revenue.
Although the company has secured IDE approvals and breakthrough status, final FDA clearance is still pending. The timeline for clearance can be unpredictable, and any delays—whether due to additional data requirements or adverse safety findings—could postpone market entry by months or even years. A delayed approval would postpone the onset of commercial revenue and prolong the company’s reliance on internal funding. Such regulatory uncertainty is a substantial risk that is not fully priced into the current valuation.
The atrial fibrillation market is already crowded with established technologies such as cryoablation and radiofrequency ablation, as well as emerging competitors exploring nanosecond pulse field ablation. Pulse’s advantage lies in early efficacy data, yet competitors may launch their own devices with similar or superior performance, eroding Pulse’s potential market share. In a commoditized market, the ability to maintain pricing power is fragile, especially if payers negotiate discounts based on comparative effectiveness data. The company faces a challenging competitive landscape that could constrain growth.

Net losses of $19.4 million in Q3 reflect a high burn environment that is not yet offset by meaningful revenue. Stock‑based compensation rose to $5.6 million, constituting 38% of the year‑over‑year increase in expenses, signaling potential dilution and shareholder value erosion. The company’s cash runway, while sufficient at present, is being consumed at a rate that may necessitate additional fundraising before commercialization yields revenue. If the company cannot secure strategic financing or equity infusions, it risks running out of capital while still investing heavily in clinical studies.
The bulk of procedural volume is still confined to pilot programs and clinical trials, with only a modest $86,000 in revenue. The conversion of these pilots into fully commercial accounts is uncertain; the company has yet to demonstrate that practitioners will adopt the technology at scale beyond early adopters. If the transition stalls, the revenue pipeline will remain thin, limiting the ability to cover operating costs and invest in growth. This scenario exposes the business to a prolonged period of negative earnings and cash depletion.
Payer coverage remains unestablished for many of the company’s indications. While preliminary claims data are positive, the absence of a clear reimbursement framework could delay or reduce the reimbursement rates for procedures performed under the technology. Payers may demand robust real‑world evidence before granting full coverage, and delays in reimbursement approvals could compress margins for early adopters. The company’s ability to secure favorable payer terms is therefore a critical, but currently uncertain, driver of revenue.
Although the company has secured IDE approvals and breakthrough status, final FDA clearance is still pending. The timeline for clearance can be unpredictable, and any delays—whether due to additional data requirements or adverse safety findings—could postpone market entry by months or even years. A delayed approval would postpone the onset of commercial revenue and prolong the company’s reliance on internal funding. Such regulatory uncertainty is a substantial risk that is not fully priced into the current valuation.
The atrial fibrillation market is already crowded with established technologies such as cryoablation and radiofrequency ablation, as well as emerging competitors exploring nanosecond pulse field ablation. Pulse’s advantage lies in early efficacy data, yet competitors may launch their own devices with similar or superior performance, eroding Pulse’s potential market share. In a commoditized market, the ability to maintain pricing power is fragile, especially if payers negotiate discounts based on comparative effectiveness data. The company faces a challenging competitive landscape that could constrain growth.

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	160.71 Bn	56.57	15.97	-
2	BDX	Becton Dickinson & Co	44.07 Bn	25.25	2.01	19.54 Bn
3	ALC	Alcon Inc	36.32 Bn	37.03	3.52	4.74 Bn
4	RMD	Resmed Inc	32.65 Bn	22.09	6.05	0.26 Bn
5	HOLX	Hologic Inc	22.91 Bn	31.25	5.55	2.51 Bn
6	WST	West Pharmaceutical Services Inc	19.22 Bn	37.36	6.25	0.20 Bn
7	COO	Cooper Companies, Inc.	13.67 Bn	34.50	3.29	2.50 Bn
8	ALGN	Align Technology Inc	12.17 Bn	30.13	3.02	-

Research Tools

Pulse Biosciences, Inc. (NASDAQ: PLSE)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Research Tools

Pulse Biosciences, Inc. (NASDAQ: PLSE)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password